Jardiance is FDA-approved for heart failure with reduced or preserved ejection fraction. If denied for this indication, this guide covers the specific clinical evidence and guideline support for your appeal.
Jardiance Heart Failure Indications
- HFrEF (reduced ejection fraction, EF ≤ 40%) — FDA approved
- HFpEF (preserved ejection fraction, EF > 40%) — FDA approved
- Reduces hospitalization and cardiovascular death
Common Denial Reasons
- Plan only covers Jardiance for diabetes
- Step therapy requiring other HF medications first
- Classified as "diabetes drug" not "heart failure drug"
- Prior authorization criteria based on outdated guidelines
Appeal Strategy
Clinical Evidence
- EMPEROR-Reduced trial: 25% reduction in CV death/HF hospitalization
- EMPEROR-Preserved trial: First drug to show benefit in HFpEF
- ACC/AHA 2022 Guidelines: SGLT2 inhibitors are Class I recommendation for HF
Key Arguments
- FDA approval specifically includes heart failure (not just diabetes)
- ACC/AHA guidelines give Class I (strongest) recommendation
- Jardiance reduces mortality — this isn't optional, it's life-saving
- No adequate substitute — SGLT2 inhibitors are a unique drug class for HF
Required Documentation
- Cardiologist letter citing EMPEROR trials and ACC/AHA guidelines
- Echo report showing ejection fraction
- Current medication list showing guideline-directed medical therapy
- NT-proBNP levels if available